COMPUMEDICS LIMITED — AGM Information 2025

Oct 29, 2025

Annual General Meeting 2025 10.30am Thursday 30[th] October 2025

==> picture [348 x 54] intentionally omitted <==

==> picture [529 x 105] intentionally omitted <==

==> picture [432 x 105] intentionally omitted <==

==> picture [529 x 73] intentionally omitted <==

Annual General Meeting

Agenda

1. Meeting opens

2. Chairmans address and update

3. Ordinary business

4. Meeting closes

Business Snapshot

==> picture [529 x 73] intentionally omitted <==

Compumedics (ASX: CMP) is a leading global medical technology company focused on sleep, neurological disorders and ultrasonic brain blood flow monitoring.

Technology Australia based, developer/leader in with wholly owned Long track record, Compumedics’ offices in the USA, having been respective end Germany, France, founded in 1987 markets, with over Austria and Korea and listed on the 30,000 systems and a network of ASX since 2000 installed worldwide 100+ distributors to date globally

==> picture [59 x 60] intentionally omitted <==

==> picture [341 x 112] intentionally omitted <==

----- Start of picture text -----

Generated $51m of
Global team revenue in FY25.
comprised of Revenue guidance
~180 people $52M of A$70M+ and
across 6 EBITDA of ~A$9M
countries in FY26
----- End of picture text -----

Compumedics has a number of leading market positions

B2B business model with leading blue-chip customer base

China

Australian Japan #1 Sleep and neuro *** Sleep and neuro diagnostics diagnostics supplier supplier

1 Sleep diagnostics device supplier to premier facilities (and #1 TCD supplier)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

Germany #1 TCD Supplier

USA

Sleep diagnostics device supplier and emerging #3 supplier for neurological monitoring devices

• Compumedics sells directly to end-user customers in Australia, USA, France and Germany and through its network of more than 100 distributors to all other parts of the world

• Key customers include hospitals, doctors/clinics, universities and research organisations

==> picture [378 x 68] intentionally omitted <==

Executive Summary

==> picture [529 x 73] intentionally omitted <==

Delivering Record Revenues and Scalable Growth Across Global Healthcare Markets

Record Sales Orders $63.4M Up +22% on FY24 Up +49% on FY23

Record Sales Revenue $51.0M Up +2% on FY24, +15% excl MEG Up +20% on FY23

==> picture [41 x 10] intentionally omitted <==

----- Start of picture text -----

EBITDA
----- End of picture text -----

==> picture [251 x 112] intentionally omitted <==

----- Start of picture text -----

$2.9M
Up +9% on FY24
----- End of picture text -----

Major Contract Wins

• Best Med $5M p.a. over 4-years: multi-year SaaS + disposables contract

• Phillips $3M over 5-years: Australian pharmacybased HST program leveraging Somfit platform

• Virtuox $3M p.a. over 5-years: national U.S. sleep diagnostics rollout

• Persante $3M over 3-years: leading U.S. sleep provider signed for Somfit platform

Core Priorities

• U.S. expansion accelerating across sleep, neurology, and research segments

• Somfit SaaS gaining traction in U.S., EU & AU markets

• Three MEG orders progressing , and scheduled for FY26 delivery

• DWL transformation to enable profitable, scalable growth

• U.S. install base driving recurring revenue from consumables and customer care

• EBITDA uplift delivered through scale, mix optimisation, and cost discipline

Growth Drivers

• Drive Growth Across All Segments by scaling SaaS, hardware, and consumables, and converting Somfit, MEG, and Care into recurring revenue engines

• Expand Global Footprint through deeper U.S. penetration and strategic growth across Europe and Asia via partners and distribution

• Invest in Next Leg of Growth by launching Somfit-D and robotic TCD, backed by continued investment in R&D, systems, and leadership scale-up

• Unlock Transformational Upside with Somfit SaaS (~$250M to $10B) and OrionMEG® LifeSpan (~$13.6B) long-term market potential

FY25 Financial Results

==> picture [529 x 73] intentionally omitted <==

Compumedics is delivering strong growth supported by multiple growth opportunities and disciplined cost control

Sales Orders ($M)

==> picture [276 x 378] intentionally omitted <==

----- Start of picture text -----

Record sales orders FY25 up +22% YoY
75.0
63.4
51.9
42.5
37.80
FY22A FY23A FY24A FY25A FY26F
Somfit & SaaS Sales Orders ($M)
Record Somfit & SaaS Revenue: 11% of total revenue (9% in FY24)
10.0
6.7
4.5
3.5
1.4
FY22A FY23A FY24A FY25A FY26F
----- End of picture text -----

Sales Revenue ($M)

==> picture [274 x 175] intentionally omitted <==

----- Start of picture text -----

Record sales revenue FY25 up +3% YoY
70.0
51.0
49.1
40.4
37.8
FY22A FY23A FY24A FY25A FY26F
----- End of picture text -----

EBITDA ($M)

==> picture [275 x 178] intentionally omitted <==

----- Start of picture text -----

EBITDA: $2.9M (margin expansion in H2 FY25)
9.0
3.3 2.7 2.9
FY22A FY23A FY24A FY25A FY26F
-2.0
----- End of picture text -----

USA Sales Orders ($M)

==> picture [274 x 174] intentionally omitted <==

----- Start of picture text -----

Record USA sales orders up +118% YoY
30.0
20.9
10.9 10.3 9.6
FY22A FY23A FY24A FY25A FY26F
----- End of picture text -----

Key Takeaways

Compumedics Performance

• CMP produced YoY growth across all major financial metrics in FY25

• H2 FY25 performance provides baseline run rate to target material earnings growth in FY26

Market Overview & Performance

• Strong tailwinds across sleep, neurology, and neuroimaging markets

• Rising global demand for home-sleep-test (HST) diagnostics and SaaSenabled solutions

• MEG and TCD gaining traction as next-gen brain & stroke diagnostics

• Strategic markets (USA, China, EU) recovering post-COVID with strong growth

• Compumedics gaining share in high-margin, high-tech segments

Sleep & SaaS

==> picture [529 x 73] intentionally omitted <==

SaaS-Driven Sleep Diagnostics Leadership: High-Growth Momentum, Scalable Model, Global Traction

Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity	Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity
Sleep: Clinical Diagnostics	46%	• Strong growth from installed base of 25,000+ system • Market share of 30–40% in high-end sleep diagnostics • Long-term partnership with Philips to drive recurring sales • Global channel scale and 35+ years of sleep R&D		• World leader in sleep diagnostics hardware • Comprehensive offering from full PSG systems to portable solutions • Trusted by hospitals, sleep labs, and specialists globally	Grael: Full PSG systems for clinical sleep testing
Somfit & Nexus 360 SaaS	13%	• FY25 revenue $6.7M (up +49% YoY) • $3M p.a. agreement with Philips AU • U.S. launch: $3M revenue to date with $10M pipeline • Targeting 100K+ Somfit units over 5 years • Somfit & SaaS to reach ~50% of Sleep revenue by FY27	• USA HST market growing ~25% p.a., underpinned by 60M to 80M undiagnosed Americans • Somfit targets a $150M to $300M p.a. U.S. HST market • Upside: ~$250M U.S. reimbursement, ~$1B global reimbursement • Consumer health potential ~$1B to $10B with tech partners • Rapidly scaling cloud-based platform • Enhancing device connectivity, monitoring, and remote diagnostics • Recurring revenue stream with strong margin profile Somfit / Somfit Pro:Wearable diagnostic devices Nexus 360: Web-based lab & patient management

Neuro Monitoring & Research

Pioneering Neurotech with Scalable MEG Growth and Global Clinical Traction

Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research	Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research	Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research	Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research	Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research	Neuro – Clinical Monitoring (non-MEG) Okti: High-definition wireless EEG Quik-Cap Arrays: EEG electrodes Neuroscience Lab Suite Business % FY25 Sales Orders Growth & Strategic Highlights Example Products / Solutions (Not Exhaustive) Market Positioning & Opportunity 15% • Wireless Okti EEG adoption expanding • Neurology lab footprint growing in EU & U.S. • Strong cross-sell potential with MEG and Sleep • Platform integration opportunities across diagnostics • Trusted clinical solutions for epilepsy and neurology • Full suite of EEG systems, amplifiers, recorders • Alternative to Natus/Micromed in key markets Brain – Research CURRY: Multimodal neuroimaging platform Neuroscan: Research EEG amplifiers and software 14% • Neuroscan used in 1,500+ universities/labs across 40+ countries • Advanced analytics driving neuroscience research • Broad R&D appeal: cognitive, sensory, sleep research • Leading provider of research-grade EEG systems • Highly defensible segment with long- term customer base • Scalable product suite supporting top- tier research
MEG	12%	• FY24 MEG revenue: $4.7M • $15M+ orders for delivery in FY26 • TJNU China site now live, three more systems in pipeline • Market acceleration providing further growth opportunity		• Expansion into paediatric MEG lifts near- term opportunity to ~$120M p.a. • High-growth MRI alternative • Long-term upside: OrionMEG® LifeSpan could scale to ~$13.6B if adoption follows MRI trajectory • Expanding in U.S., EU, and China with major centres	Orion Lifespan MEG:Superior functional imaging with unmatched temporal resolution

==> picture [529 x 73] intentionally omitted <==

Bloodflow & TCD (DWL)

AI-Driven TCD Innovation: Commercial Momentum in a $12B Stroke Market

Example Products / Solutions (Not Exhaustive)

• % FY25 Example Products / Solutions

• Business Sales Orders Growth & Strategic Highlights Market Positioning & Opportunity (Not Exhaustive)

• Bloodflow & TCD (DWL) • FY25 revenue of $4.5M (typically ~$6M) with growth resuming post-China • • Positioned to disrupt a $12B+ global

• regulatory resolution Positioned to disrupt a $12B+ global stroke diagnostics market with realstroke diagnostics market with real-

• • time, non-invasive blood flow imaging Relaunch of Ez-Dop targeting premium time, non-invasive blood flow imaging hospital market •• Robotic AI-enhanced TCD offers scalable Robotic AI-enhanced TCD offers scalable DWL AI Robotic TCD

• • point-of-care solution with minimal Prototype: Robotic TCD platform advancing toward point-of-care solution with minimal

• 9% commercialisation within 12–24 months operator dependencyoperator dependency Portable module that supports use in various

• •

• • • Compumedics DWL has a strong brand positions. Targeting large unmet needs in stroke, Compumedics DWL has a strong brand presence in neurology and neurocritical

• TBI, and neuro ICU markets presence in neurology and neurocritical care globally care globally

• • Strategic partner discussions underway to fast-track commercial deployment

Annuity Revenue Streams

28% of FY25 total revenues – SaaS, Service and consumables

Business % FY25 Sales Orders Growth & Strategic Highlights	Business % FY25 Sales Orders Growth & Strategic Highlights	Business % FY25 Sales Orders Growth & Strategic Highlights
Somfit & Nexus 360 SaaS	13%	• FY25 revenue $6.7M (up +49% YoY) • $3M p.a. agreement with Philips AU • U.S. launch: $3M revenue to date with $10M pipeline • Targeting 100K+ Somfit units over 5 years • Somfit & SaaS to reach ~50% of Sleep revenue by FY27
Consumables & Customer Care (NeuroMedical Supplies)	15%	• FY25 revenue of $7.8M, underpinned by global installed base • Strong annuity-style revenue stream supporting enterprise-wide recurring model • Supply chain optimised for scalable throughput and cost efficienc • Expansion of hardware and support aligned to growing SaaS install base

Market Positioning & Opportunity

• USA HST market growing ~25% p.a., underpinned by 60M to 80M undiagnosed Americans

• • Somfit targets a $150M to $300M p.a. U.S. HST market

• • Upside: ~$250M U.S. reimbursement, ~$1B global reimbursement

• Somfit D unlocks large-scale disposable opportunity linked to 100K+ device units

• High-margin, predictable revenue stream supporting SaaS lifecycle value

• Consumables model increases customer lifetime value and retention across modalities

• Platform enables leverage into broader wellness and diagnostics services ecosystem

Example Products / Solutions (Not Exhaustive)

==> picture [144 x 73] intentionally omitted <==

Somfit / Somfit Pro: Wearable diagnostic devices

Okti® Child Disposable Backpack

Wearable, single-use EEG harness

Growth & Outlook

==> picture [529 x 73] intentionally omitted <==

2HFY25 financial performance and record orders and run rate provides a baseline target for FY26

Growth Opportunities

==> picture [50 x 52] intentionally omitted <==

Continued expansion in the USA across all products (e.g. currently ~80% of people with a sleep disorder go undiagnosed in the US, significant market potential for Compumedics).

==> picture [50 x 52] intentionally omitted <==

Continued growth in Somfit SaaS revenues, notably in the USA (fastest growing HST market segment).

==> picture [50 x 48] intentionally omitted <==

Continued geographical expansion (incl. Somfit expansion into Europe).

FY26 Target

• Revenue growth of +37% YoY to $70.0M

• Sustained EBITDA to $9.0M and continued margin expansion

• Path to consistent profitability and positive free cash flow

Short to Medium Term

• Launch Somfit-D in U.S. and scale commercial uptake across sleep clinics and providers

• Build MEG orders and leverage strong global pipeline

• Drive margin uplift through disciplined cost control, product mix shift, and operational leverage

==> picture [50 x 49] intentionally omitted <==

==> picture [50 x 50] intentionally omitted <==

Continued strong momentum of MEG orders .

New product development (e.g. Somfit D (disposable) being released to US market in mid FY25).

Long Term

• Transformational Upside: Somfit SaaS (U.S. HST market growing ~25% p.a., underpinned by 60 to 80M undiagnosed Americans; ~$250M U.S. reimbursement; ~$1B global reimbursement; ~$1B to $10B consumer health) and OrionMEG® LifeSpan (~$13.6B if MRI adoption trajectory repeats)

• Build full-stack SaaS platform for sleep health with integrated diagnostics and remote care

==> picture [50 x 51] intentionally omitted <==

Continued development of DWL’s new AI robotic TCD offering (providing additional value-add analytics on top of DWL’s world-class precision TCD technology).

• Commercialise AI-enabled robotic TCD to transform brain monitoring precision

• Expand into new verticals including pharma, cardiology, and metabolic health with recurring revenue focus

Breakout Growth Platforms

Somfit ® SaaS

OrionMEG®

• Somfit ® SaaS – $6.7m (+49%), FDA cleared,

• 700k studies, $10m+ U.S. pipeline; Philips Pharmacy Strategic Partnership; Resmed Major Client; Major Deals: Big Pharmaceutical Co’s & related Contract Research Organisations.

• OrionMEG ® – 3 systems in FY26 (~$15m revenue), $20m sales in start-up phase (China alone) U.S. entry underway; Independent UCSD validation confirming global leadership status.

• Nexus 360 ® SaaS – >800k studies, expanded enterprise workflows.

• Neuroscan®/OKTI ® – Revenue doubled, CURRY ® sales +15%.

• DWL ® – FDA/EU MDR approved EZ-Dop ®, AI Robotic TCD in development.

• Alpha Trace ® – €1m sales, Kepler Clinics contract.

• OrionMEG®: ~$13.6B (10% MRI-equivalent adoption) Renewed CMP Board to Access Market.

• Somfit ® SaaS: USA reimbursement market ~$250m – growth 25% PA - CMP fastest growing AI Sleep (HST/SaaS).

• Global reimbursement: ~$1B.

• Consumer potential: $1–10B (Apple/Google/Amazon partnerships)- Renewed CMP Board to Access Market.

FY25 Highlights - At a Glance

FY25 Highlights - At a Glance

==> picture [36 x 29] intentionally omitted <==

==> picture [12 x 15] intentionally omitted <==

==> picture [19 x 24] intentionally omitted <==

Expansion Strategic into Pharma Deals

$6.7M 11% $20M + Of total company Pipeline post revenue U.S. launch & FDA approval

• $3m PA Philips

• $2m initial orders from two global pharma companies

Somfit© & SaaS revenue (up from $4.2m in FY24)

• Top Tier U.S. IDTFs

• Global leading Somfit© SaaS Pharma CRO and big Pharma

• Further trials expected FY28

Regulatory Scientific Broader Business Milestones Validation Progress

Positioned for FY26 Growth

==> picture [11 x 8] intentionally omitted <==

==> picture [17 x 17] intentionally omitted <==

==> picture [9 x 7] intentionally omitted <==

• Approvals: Brazil, • 3 peer-reviewed Colombia, Hong publications Kong, Singapore •

• Total over 770,000 Somfit© and NEXUS360© SaaS studies

  • Somfit© expansion, product launches and new market entry

• Somfit SaaS secures 75% AU HST pharmacy market

• More in progress to

• • U.S. Somfit© Pro U.S. strengthen adoption FDA in process for early ‘26FY

==> picture [33 x 33] intentionally omitted <==

==> picture [34 x 34] intentionally omitted <==

==> picture [45 x 33] intentionally omitted <==

==> picture [24 x 25] intentionally omitted <==

U.S. Market

Validation

Innovation Edge

$20M

Launch in ‘26

“Leading-edge OrionMEG© LifeSpan dual whole-head MEG system from Compumedics

World-first OrionMEG© LifeSpan:

‘25: Four

USA as the world’s largest • Compumedics MEG market, will now bolster CMP MEG progress is truly a state-of-the-art MEG system.” • ‘25: Prof. Mingxiong Huang UCSD Dep. in China, the world’s fastest growing market Rad.& Dep. Elect. & Comp. Eng., Co-Direct. MEG Centre, Scientist & Physicist • VA San Diego (ASX: CMP: 30 Sep25)

• Unique dual-helmet child/adult

• Compumedics MEG labs for total of about $20m in

Virtual 100% coolant recycling 24/7 operation

• revenues, in China alone

• CURRY MEG s/w years ahead of competitors

• Total non-invasive technique

Positioned for FY26 Growth

Manufacturing Growth

Board

==> picture [36 x 46] intentionally omitted <==

Strengthened

==> picture [9 x 8] intentionally omitted <==

Plan to launch latest OrionMEG© LifeSpan USA, China

NED MEG Major Factory expansion Strategic Deal and MSR installed Laser Focus

Positioned for Transformational Growth & Re-Rating

Why Invest Now

• Large, under-penetrated global markets (sleep & neuro diagnostics).

• Scalable SaaS recurring revenues.

• FDA/CE approvals reduce execution risk

• Strategic Board renewal with U.S. MedTech leadership onboard- Accelerate Strategic Partner Engagement & Market Access.

• CMP ~1x revenues vs peers at 4–8x - substantial investor intrinsic value- realisation.

Valuation Gap

Compumedics’ Valuation Gap

==> picture [89 x 117] intentionally omitted <==

----- Start of picture text -----

$
Current Intrinsic
Share Value
Price
Valuation Gap
----- End of picture text -----

==> picture [297 x 112] intentionally omitted <==

----- Start of picture text -----

8x revenue
6x revenue
4x revenue
1x revenue
Market
capitalisation
AU$55-60m
CMP Current Conservative Premium Illustrative
AU$55-60m AU$220-240m AU$330-360m AU$440-480m
----- End of picture text -----

==> picture [529 x 73] intentionally omitted <==

Annual General Meeting

Ordinary Business

Item 1

Financial Statements and Reports

Item 2

Election of a Director – Chris Barys

Adoption of Remuneration Report (non-binding resolution)

Item 3

Disclaimer

==> picture [529 x 73] intentionally omitted <==

This presentation has been prepared by Compumedics Limited (CMP).

While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation.

This presentation may contain forward looking statements. These forward-looking statements have been made based upon CMP’s expectations and beliefs concerning future developments and their potential effect on CMP (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond CMP’s control. No assurance is given that future developments will be in accordance with CMP’s expectations. Actual results could differ materially from those expected by CMP.

This presentation does not constitute an offer to sell or a solicitation of an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service.

Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective.

The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular investment needs.

Thank You

==> picture [529 x 73] intentionally omitted <==